NEW YORK, Dec. 23, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of TerraVia Holdings, Inc. securities (NASDAQ:TVIA) from August 8, 2016 through November 7, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for TerraVia investors under the federal securities laws.
To join the TerraVia class action, go to http://www.rosenlegal.com/cases-989.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) TerraVia’s products caused gastrointestinal distress, such as nausea and vomiting; and (2) as a result, Defendants’ statements about TerraVia’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times. On November 7, 2016, Bloomberg reported that TerraVia sent a letter to a distributor in July warning that TerraVia had received reports showing that algal protein can cause gastrointestinal distress. On this news, shares of TerraVia fell $0.15 per share or over 8% to close at $1.70 per share on November 7, 2016, damaging investors.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 17, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-989.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Apple Turns 50: From Garage Startup to AI Crossroads
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 



